Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN) [Phase 1, Phase 2]

View source ↗

Summary

Denali Therapeutics is evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of DNL593 in healthy volunteers and in individuals with Front…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Frontotemporal Dementia

Drugs mentioned

• DNL593

Snippet

Sponsor: Denali Therapeutics Inc. | Conditions: Frontotemporal Dementia | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING